We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc
MRNS

Delisted

MRNS was delisted on the 10th of February, 2025.

Back to rankings

73 hedge funds and large institutions have $180M invested in Marinus Pharmaceuticals, Inc in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 9

107% more capital invested

Capital invested by funds: $87M → $180M (+$92.7M)

82% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 17

73% more call options, than puts

Call options by funds: $5.01M | Put options by funds: $2.9M

22% more funds holding

Funds holding: 60 → 73 (+13)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
73
Holders Change
+13
Holders Change %
+21.67%
% of All Funds
1.67%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
19
Reduced
9
Closed
17
Calls
$5.01M
Puts
$2.9M
Net Calls
+$2.11M
Net Calls Change
+$1.57M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.2M
2
TBC
Three Bays Capital
Massachusetts
+$5.33M
3
State Street
State Street
Massachusetts
+$2.82M
4
VMI
VHCP Management II
New York
+$1.91M
5
Northern Trust
Northern Trust
Illinois
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
GC
GMT Capital
Georgia
-$4.84M
2
Millennium Management
Millennium Management
New York
-$2.34M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.25M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.61M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$28.1M – – –
Jennison Associates
2
Jennison Associates
New York
$19.5M +$120K +5,433 +0.8%
BlackRock
3
BlackRock
New York
$18.7M +$11.2M +503,693 +317%
GPCM
4
Granite Point Capital Management
Massachusetts
$18.7M – – –
Franklin Resources
5
Franklin Resources
California
$13.6M +$1.44M +65,125 +16%
TBC
6
Three Bays Capital
Massachusetts
$13.5M +$5.33M +240,292 +102%
Vanguard Group
7
Vanguard Group
Pennsylvania
$11.1M +$1.51M +68,015 +21%
6CM
8
683 Capital Management
New York
$8.48M – – –
PA
9
Perceptive Advisors
New York
$6.42M – – –
O
10
OrbiMed
New York
$4.01M – – –
State Street
11
State Street
Massachusetts
$3.89M +$2.82M +127,189 +1,211%
AG
12
Artal Group
Luxembourg
$3.54M – – –
CAM
13
Cormorant Asset Management
Massachusetts
$3.38M – – –
Northern Trust
14
Northern Trust
Illinois
$2.74M +$1.85M +83,389 +626%
MWNA
15
Marshall Wace North America
New York
$2.68M +$1.57M +70,978 +297%
VMI
16
VHCP Management II
New York
$2.44M +$1.91M +86,310 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.91M +$587K +26,493 +65%
TCIM
18
TIAA CREF Investment Management
New York
$1.61M +$1.26M +56,913 New
HT
19
HAP Trading
New York
$1.54M -$899K -40,537 -43%
QIM
20
Quantitative Investment Management
Virginia
$1.14M +$897K +40,475 New
Millennium Management
21
Millennium Management
New York
$1.11M -$2.34M -105,552 -73%
CS
22
Credit Suisse
Switzerland
$944K +$740K +33,387 New
VEA
23
Virtus ETF Advisers
New York
$778K +$164K +7,401 +37%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$754K +$387K +17,466 +190%
JP Morgan Chase
25
JP Morgan Chase
New York
$751K +$47K +2,122 +9%
1
2 3 4

MRNS Hedge Fund Activity: Q2 2018 in Review

73 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2018, worth a combined $180M — up 107% from $87M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new MRNS positions and 17 closed out — a net gain of 14 holders — while 19 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $11.2M. The largest seller was GMT Capital, exiting entirely with an estimated $4.84M sold.

  • 73 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2018, up from 60 in Q1 2018.
  • Funds reported $180M of Marinus Pharmaceuticals, Inc stock for Q2 2018, up 107% quarter-over-quarter.
  • 31 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2018 and 17 closed out, a net change of +14 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q2 2018 was BlackRock, an estimated $11.2M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q2 2018 was GMT Capital, an estimated $4.84M sold.

Based on aggregated 13F filings for Q2 2018.